Global Pulmonary Arterial Hypertension Market to reach USD 7.41 billion by 2027.Global Pulmonary Arterial Hypertension Market is valued approximately at USD 5.3 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 4.9% over the forecast period 2021-2027. Pulmonary Arterial Hypertension is a kind of high blood pressure which affects arteries in the lungs area and cause heart related problems. The global Pulmonary Arterial Hypertension market is being driven by rising incidents of Pulmonary Arterial Hypertension (PAH) and growing geriatric population. Furthermore, the government support for development of orphan drugs will provide new opportunities for the global Pulmonary Arterial Hypertension industry. For instance, according to the study of an American College of Cardiology, in year 2020, the incidence rate of COVID-19 infection in PAH patients was 2.1 cases per 1,000 patients. This increased the demand for PAH drugs for its treatment to manage the risk of COVID-19 infection. As a result, increased in PAH patients and related diseases will serve as a catalyst for the Pulmonary Arterial Hypertension industry in the future. However, patent expiration of key molecules may impede market growth over the forecast period of 2021-2027.

Asia Pacific, North America, Europe, Latin America, and Rest of the World are the key regions considered for the regional analysis of global Patent Expiration of Key Molecules market. The improving healthcare systems and rapid economic developments as well as large population base makes Asia Pacific the leading region across the world in terms of market share. Whereas Asia pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to high burden of diseases, such as HIV and diabetes in the region.
Major market player included in this report are:

Johnson & Johnson Services, Inc
Gilead Sciences, Inc.
United Therapeutics Corporation
Acceleron Pharma, Inc.
GlaxoSmithKline Plc. (GSK)
Pfizer, Inc.
Bayer AG
Novartis International AG
Dong-A ST Co., Ltd.
Merck Sharp & Dohme Corp.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drugs Class:
Prostacyclin and Prostacyclin Analogs
Soluble Guanylate Cyclase (SGC) Stimulators
Endothelin Receptor Antagonist (ERA)
Phosphodiesterase 5 (PDE-5)

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Pulmonary Arterial Hypertension Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors